SecBot SecBot
8-K ·Filed Feb 26, 2026

MNKD

MANNKIND CORP
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001193125-26-073509
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of strong revenue growth, successful integration of scPharma, and upcoming FDA catalysts in 2026 suggests potential for continued momentum. Traders should monitor the PDUFA decisions for Afrezza pediatrics and Furoscix ReadyFlow as key value inflection points.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.24
T+0 close · Feb 26, 2026 · via day close
Latest settled
+2.16%
T+60 · $3.31
Vs SPY
−5.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $3.24entry
  2. T+1 · 9mo ago +1.23%α +1.69% · $3.28
  3. T+5 · 9mo ago −12.65%α −11.53% · $2.83
  4. T+20 · 8mo ago −29.01%α −22.61% · $2.30
  5. T+60 · 6mo ago +2.16%α −5.59% · $3.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind reported strong fourth quarter and full year 2025 financial results, with Q4 revenue up 46% year-over-year to $112 million and full year revenue up 22% to $349 million, driven by the acquisition of scPharma and growth in Afrezza and Furoscix sales. The company also highlighted upcoming FDA catalysts for Afrezza in pediatrics and Furoscix ReadyFlow Autoinjector.

Key Financial Metrics

Revenue
$112.0M
+46.0% YoY
Adj. EPS
$0.01
GAAP: $-0.05

Key Facts

  • Q4 2025 revenue was $111.96 million, a 46% increase from $76.78 million in Q4 2024
  • Full year 2025 revenue was $348.97 million, up 22% from $285.50 million in 2024
  • Furoscix generated $23.18 million in net sales following the October 2025 acquisition of scPharma
  • Afrezza Q4 2025 net sales were $22.88 million, up 25% from Q4 2024
  • Company has $176 million in cash, cash equivalents, and investments as of December 31, 2025
  • FDA accepted sBLA for Afrezza in pediatrics with PDUFA date of May 29, 2026
  • FDA accepted sNDA for Furoscix ReadyFlow Autoinjector with PDUFA date of July 26, 2026

Financial Impact

Revenue growth of $63.46 million year-over-year, driven by acquisition and product sales growth

revenuecommercial product salescash

Segment Breakdown

SegmentRevenueGrowth
Afrezza$22.9M+25.0%
Furoscix$23.2MNot reported
Royalties$33.6M+24.0%

Risk Factors

  • Net loss of $15.95 million in Q4 2025 despite revenue growth, indicating ongoing profitability challenges
  • Significant increase in SG&A expenses (144% YoY) and R&D expenses (148% YoY) could pressure margins
  • Dependence on regulatory approvals for future growth, with inherent uncertainty in FDA decisions

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-073509
Document: mnkd-20260226.htm0001193125-26-073509
Document: 0001193125-26-073509-index-headers.html0001193125-26-073509
Document: 0001193125-26-073509-index.html0001193125-26-073509
Document: 0001193125-26-073509.txt0001193125-26-073509

Track record

17 reports on MNKD

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026